Drugs / AZD5312
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03300505 | May 2019 → Jan 2023 | prostate cancer | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT02144051 | May 2014 → Mar 2016 | — | AstraZeneca | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-11-20 | Ionis Pharmaceuticals | Results ISIS-STAT3 Rx and ISIS-AR Rx Data Presented by AstraZeneca at European Cancer Symposium ionis.com ↗
In addition, AstraZeneca will also present preclinical data on ISIS-ARRx (AZD5312) showing that the drug is active in several tumor models. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-11-20 | Ionis Pharmaceuticals | ISIS-STAT3 Rx and ISIS-AR Rx Data Presented by AstraZeneca at European Cancer Symposium ionis.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5312 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02144051 ↗ |
| Known as | ARRx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03300505 ↗ |
| Known as | ISIS-ARRX | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297901 ↗ |
| Known as | ISIS-AZ1RX | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297901 ↗ |
| Action | Inhibit | “specifically suppressing human Androgen Receptor (AR) expression” NCT02144051 ↗ |
| Modality | Antisense oligonucleotide | “generation 2.5 antisense oligonucleotide (ASO)” NCT02144051 ↗ |
| Route | Intravenous | “AZD5312 will be given intravenously (IV) as an infusion” NCT02144051 ↗ |
| Target | AR | “suppressing human Androgen Receptor (AR) expression” NCT02144051 ↗ |